CYCLO THERAPEUTICS INC (CYTH) Stock Price, Quote, News and Overview
NASDAQ:CYTH - Nasdaq - US23254X2018 - Common Stock - Currency: USD
CYTH Quote, Performance and Key Statistics
0.7206
+0.01 (+1.39%)
The current stock price of CYTH is 0.7206 USD. In the past month the price decreased by -5.31%. In the past year, price decreased by -48.16%.
CYTH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.17 | 307.41B | ||
| AMGN | AMGEN INC | 14.05 | 149.68B | ||
| GILD | GILEAD SCIENCES INC | 22.89 | 131.53B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1691.28 | 126.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 64.01B | ||
| ARGX | ARGENX SE - ADR | 322.51 | 36.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.80B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.17B | ||
| NTRA | NATERA INC | N/A | 19.55B | ||
| BIIB | BIOGEN INC | 7.22 | 17.40B |
Related stock screener links
About CYTH
Company Profile
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 8 full-time employees. The company went IPO on 2004-02-27. The Company’s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C1, a rare and fatal genetic disease, (NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The firm is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
Company Info
CYCLO THERAPEUTICS INC
6714 Nw 16Th Street, Suite B
Gainesville Florida FLORIDA 32653 US
CEO: N. Scott Fine
Employees: 8
Company Website: https://www.cyclotherapeutics.com/
Investor Relations: http://cyclotherapeutics.com/overview/
Phone: 13864188060
CYCLO THERAPEUTICS INC / CYTH FAQ
What is the stock price of CYCLO THERAPEUTICS INC today?
The current stock price of CYTH is 0.7206 USD. The price increased by 1.39% in the last trading session.
What is the ticker symbol for CYCLO THERAPEUTICS INC stock?
The exchange symbol of CYCLO THERAPEUTICS INC is CYTH and it is listed on the Nasdaq exchange.
On which exchange is CYTH stock listed?
CYTH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CYCLO THERAPEUTICS INC stock?
9 analysts have analysed CYTH and the average price target is 0.97 USD. This implies a price increase of 34.47% is expected in the next year compared to the current price of 0.7206. Check the CYCLO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CYCLO THERAPEUTICS INC worth?
CYCLO THERAPEUTICS INC (CYTH) has a market capitalization of 23.72M USD. This makes CYTH a Nano Cap stock.
How many employees does CYCLO THERAPEUTICS INC have?
CYCLO THERAPEUTICS INC (CYTH) currently has 8 employees.
What are the support and resistance levels for CYCLO THERAPEUTICS INC (CYTH) stock?
CYCLO THERAPEUTICS INC (CYTH) has a support level at 0.69 and a resistance level at 1.1. Check the full technical report for a detailed analysis of CYTH support and resistance levels.
Is CYCLO THERAPEUTICS INC (CYTH) expected to grow?
The Revenue of CYCLO THERAPEUTICS INC (CYTH) is expected to decline by -41.47% in the next year. Check the estimates tab for more information on the CYTH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CYCLO THERAPEUTICS INC (CYTH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CYTH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CYTH, evaluating the profitability, health, valuation and growth aspects
- CYCLO THERAPEUTICS INC (CYTH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYCLO THERAPEUTICS INC (CYTH) Sales and EPS estimates to see what analysts future expectations are.
- CYCLO THERAPEUTICS INC (CYTH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYCLO THERAPEUTICS INC (CYTH) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYCLO THERAPEUTICS INC (CYTH) Stock Chart to make your own analysis
- CYCLO THERAPEUTICS INC (CYTH) Latest news and press-releases to stay up to date.
Does CYCLO THERAPEUTICS INC (CYTH) stock pay dividends?
CYTH does not pay a dividend.
When does CYCLO THERAPEUTICS INC (CYTH) report earnings?
CYCLO THERAPEUTICS INC (CYTH) will report earnings on 2025-05-13.
What is the Price/Earnings (PE) ratio of CYCLO THERAPEUTICS INC (CYTH)?
CYCLO THERAPEUTICS INC (CYTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.92).
What is the Short Interest ratio of CYCLO THERAPEUTICS INC (CYTH) stock?
The outstanding short interest for CYCLO THERAPEUTICS INC (CYTH) is 3.16% of its float. Check the ownership tab for more information on the CYTH short interest.
CYTH Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CYTH. When comparing the yearly performance of all stocks, CYTH is a bad performer in the overall market: 63.48% of all stocks are doing better.
CYTH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYTH. CYTH has a bad profitability rating. Also its financial health evaluation is rather negative.
CYTH Financial Highlights
Over the last trailing twelve months CYTH reported a non-GAAP Earnings per Share(EPS) of -0.92. The EPS increased by 44.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -472.02% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CYTH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to CYTH. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 56.84% and a revenue growth -41.47% for CYTH